Free Trial
NASDAQ:DMAC

DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis

DiaMedica Therapeutics logo
$7.07 +0.07 (+1.00%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$7.00 -0.07 (-0.98%)
As of 10/3/2025 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About DiaMedica Therapeutics Stock (NASDAQ:DMAC)

Advanced

Key Stats

Today's Range
$6.92
$7.13
50-Day Range
$4.12
$7.28
52-Week Range
$3.19
$7.49
Volume
229,505 shs
Average Volume
489,665 shs
Market Capitalization
$365.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.33
Consensus Rating
Moderate Buy

Company Overview

DiaMedica Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

DMAC MarketRank™: 

DiaMedica Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 562nd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    DiaMedica Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    DiaMedica Therapeutics has a consensus price target of $12.33, representing about 74.4% upside from its current price of $7.07.

  • Amount of Analyst Coverage

    DiaMedica Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about DiaMedica Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for DiaMedica Therapeutics are expected to decrease in the coming year, from ($0.59) to ($0.80) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of DiaMedica Therapeutics is -10.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of DiaMedica Therapeutics is -10.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    DiaMedica Therapeutics has a P/B Ratio of 7.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about DiaMedica Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.97% of the outstanding shares of DiaMedica Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    DiaMedica Therapeutics has a short interest ratio ("days to cover") of 9.2.
  • Change versus previous month

    Short interest in DiaMedica Therapeutics has recently increased by 2.23%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    DiaMedica Therapeutics does not currently pay a dividend.

  • Dividend Growth

    DiaMedica Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.97% of the outstanding shares of DiaMedica Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    DiaMedica Therapeutics has a short interest ratio ("days to cover") of 9.2.
  • Change versus previous month

    Short interest in DiaMedica Therapeutics has recently increased by 2.23%, indicating that investor sentiment is decreasing.
  • News Sentiment

    DiaMedica Therapeutics has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for DiaMedica Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    12 people have searched for DMAC on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added DiaMedica Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, DiaMedica Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,358,598.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 7.30% of the stock of DiaMedica Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 10.12% of the stock of DiaMedica Therapeutics is held by institutions.

  • Read more about DiaMedica Therapeutics' insider trading history.
Receive DMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DMAC Stock News Headlines

The Fed Just Got Kneecapped — Here’s What Happens Next
Donald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he’s kneecapped the Federal Reserve…tc pixel
DiaMedica Appoints New Chief Medical Officer
See More Headlines

DMAC Stock Analysis - Frequently Asked Questions

DiaMedica Therapeutics' stock was trading at $5.43 on January 1st, 2025. Since then, DMAC stock has increased by 30.2% and is now trading at $7.07.

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) announced its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.18) earnings per share for the quarter, hitting the consensus estimate of ($0.18).
Read the conference call transcript
.

DiaMedica Therapeutics (DMAC) raised $18 million in an initial public offering on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that DiaMedica Therapeutics investors own include NVIDIA (NVDA), ADMA Biologics (ADMA), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX), Ardelyx (ARDX) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
8/12/2025
Today
10/04/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DMAC
CIK
1401040
Fax
N/A
Employees
20
Year Founded
2000

Price Target and Rating

High Price Target
$14.00
Low Price Target
$11.00
Potential Upside/Downside
+74.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.69)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$24.44 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-78.99%
Return on Assets
-69.94%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.55
Quick Ratio
7.55

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.95 per share
Price / Book
7.44

Miscellaneous

Outstanding Shares
51,689,000
Free Float
47,916,000
Market Cap
$365.44 million
Optionable
Optionable
Beta
1.40

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:DMAC) was last updated on 10/4/2025 by MarketBeat.com Staff
From Our Partners